Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.7052W HIGH $22.00
Volume
37.66 K
Value Traded
85.69 K
Short % Float
0.31%
-6.57%Week
+67.29%1 Month
+255.5%3 Month
+1.86%6 Month
-52.64%5 Year
-70.31%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
454.10 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
330.25 M
Total Shares
70.82 M
Float Shares
14.08 M
Insiders
80.12%
Institutions
0.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
YDES Catalyst Timeline
Dated clinical, regulatory and corporate events for YD Bio Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for YD Bio Limited
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How YDES actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
YD Bio Limited is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every YDES program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shen Ethan PhDDirector, Officer (CEO) | Buy | 12,700 11,258,331 held | $3.85 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in YDES
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in YDES for Q2 2026. | ||||
YDES Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How YDES ranks across every disease it competes in
Competitive Position is a premium feature
See how YDES ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialYDES News
YDES▼ -9.1%today
YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
YD Bio Limited and EG BioMed Co., Ltd. have launched an AI Cancer Risk Assessment tool that analyzes self-reported health data to provide personalized cancer risk reports. The assessment covers ten cancer types and is available in English and Chinese for a promotional price of $10. It integrates with existing oncology services but does not diagnose cancer.
Read more →YDESYD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
YD Bio Limited reported significant financial growth for the first half of 2026, achieving a 315% increase in revenue, reaching $846,501. The company transitioned to profitability with a net income of $6.7 million, aided by strategic commercial efforts and large-scale orders. However, operational expenses rose significantly, leading to a net loss when excluding non-cash adjustments. The company is focused on expanding its diagnostic capabilities and managing capital resources effectively.
Read more →YDESYD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
YD Bio Limited announced the publication of a peer-reviewed article in the journal Nutrients, co-authored with physicians from various healthcare institutions. The article explores the connection between omega-3 fatty acids, vitamin D3, and vitamin K2 in relation to aging-related health issues. This publication marks a significant milestone in YD Bio's physician-partnership initiative, aiming to integrate clinical observations with scientific research.
Read more →YDES▲ +9%on this newsshared move
YD Bio Launches a Physician-Partnership Initiative in Taiwan with Two Chrono-Nutrition Formulations
YD Bio has launched two new chrono-nutrition formulations in Taiwan, designed for daytime and nighttime use. The 'Golden Triangle' formula for daytime and a zinc-plus-calcium formula for nighttime were co-developed with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute. This initiative aims to enhance chronic disease management through specialized nutrition.
Read more →YDESYD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
YD Bio Limited has highlighted a peer-reviewed study published in Bioengineering that introduces a new computational framework aimed at identifying regenerative targets for keratoconus. The study, co-authored with Taipei Medical University, emphasizes a data-driven approach to analyze genetic data related to corneal disease. This research aims to address the unmet need for effective regenerative therapies for keratoconus.
Read more →YDESYD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
YD Bio Limited has launched a six-month pilot collaboration with Numia Health to evaluate the scalability of blood-based cancer testing in Canada. The pilot aims to establish a cross-border clinical workflow for physician-ordered tests, focusing on various cancer types. This initiative represents YD Bio's first structured clinical-access effort in Canada, reflecting its strategy to enhance patient access to advanced diagnostics.
Read more →YDES▼ -7.7%on this newsshared move
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
YD Bio Limited and EG BioMed concluded a successful exhibition at BIO Asia-Taiwan 2026, showcasing innovations in ophthalmology and oncology diagnostics. The companies presented their advancements, including preservative-free artificial tears and DNA-based cancer detection technologies. They engaged with over 30 prospective partners, demonstrating strong interest in their integrated healthcare approach and services for U.S. market entry.
Read more →YDESYD Bio Expands U.S. Laboratory Footprint to 47 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio's affiliate, EG BioMed US, has expanded its laboratory operations to 47 U.S. states by obtaining clinical laboratory licenses in Rhode Island and Pennsylvania. This expansion enhances patient access to early cancer detection services through their CLIA-certified laboratory. The company emphasizes the importance of real-world molecular data in validating its diagnostic capabilities, while also pursuing a merger with EG BioMed, which remains subject to regulatory conditions.
Read more →YDES▼ -17.7%on this newsshared move
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio Limited has expanded its laboratory operations to 46 U.S. states by obtaining clinical laboratory licenses in Rhode Island and Pennsylvania. This expansion enhances patient access to early cancer detection services through its accredited laboratory and telehealth platform. The company views this growth as a critical step in accumulating high-quality molecular data for cancer diagnostics.
Read more →YDESYD Bio Limited Reports Full Year 2025 Financial Results
YD Bio Limited reported a transformative year in 2025, achieving a 17% increase in net revenue, primarily from pharmaceutical sales. The company strengthened its financial position through a business combination and a PIPE financing. Despite a rise in net loss to $8.3 million, YD Bio is focused on advancing its therapeutics pipeline and expanding its healthcare platform in 2026.
Read more →YDESYD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform
YD Bio Limited has announced a strategic partnership with YC Biotech Co., Ltd. to create a Taiwan-U.S. dual-core regulatory platform. This collaboration will streamline FDA-related projects, including IND, NDA, and BLA submissions. YD Bio USA will act as YC Biotech's exclusive U.S. agent, enhancing regulatory navigation for clients. The partnership aims to expand services and strengthen YD Bio's position in the U.S. regulatory landscape.
Read more →YDES▼ -9.9%on this news
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
YD Bio Limited has signed a binding Letter of Intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., enhancing its position in advanced immunocell therapy. This acquisition aims to integrate SSMC's proprietary technology into YD Bio's portfolio, focusing on personalized cancer treatments. The deal is valued at approximately NT$839.83 million and is expected to close within 30 days after due diligence.
Read more →YDESYDES 1 YD Bio Limited: Architecting the Modern Biotechnology Ecosystem Investment Deck January 2026 Forward - looking Statements 2 This presentation contains forward - looking statements within the meaning of the safe ha
YD Bio Limited has presented an investment deck outlining its strategic vision for creating a modern biotechnology ecosystem. The company plans to leverage partnerships and technology integration to enhance its operational capabilities and market position. They emphasize a disciplined U.S. expansion while addressing potential risks associated with its forward-looking statements. The focus for 2026 includes strengthening clinical evidence generation and considering strategic acquisitions to support platform capabilities.
Read more →YDES▲ +5.7%on this news
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
YD Bio Limited has announced significant milestones in its clinical and commercial roadmap for 2026, focusing on stem cell therapy and early cancer detection technologies. The company has completed critical CMC activities and filed Drug Master Files with the FDA, aiming to transition to accelerated clinical development. Despite the positive advancements, regulatory approvals and the success of future acquisitions remain uncertain.
Read more →YDESYD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection
YD Bio Limited has expanded its OkaiDx testing platform to include pancreatic and colorectal cancer detection across the U.S. The company reported promising clinical data showing high sensitivity and specificity for early-stage pancreatic cancer detection. Access to these tests is facilitated through a telehealth network and partnerships with medical groups, although the tests are not yet FDA approved.
Read more →YDES▲ +7.8%on this news
INDEX TO FINANCIAL STATEMENTS YD BIO LIMITED Unaudited Interim Financial Statements Page Condensed Consolidated Balance Sheet as of
YD Bio Limited has released its unaudited interim financial statements for the period ending June 30, 2025. The company reported a net loss of $1,239 with total liabilities and shareholder's deficit amounting to $67,680. Since its inception in February 2024, YD Bio Limited has not yet generated any revenue and continues to face financial challenges. Following a merger, the company has restructured its shareholding but remains in a deficit position.
Read more →About YD Bio Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next YDES catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime